TrialReader


Efficacy and Safety of Balloon Guide Catheter in Mechanical Thrombectomy Patients

NCT03754738 — Phase 2, Unknown, 155 participants, Capital Medical University

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT03754738, acronym ESCAPE
StatusUnknown
PhasePhase 2
Study typeInterventional; randomized, parallel, masking: double, treatment
Enrollment155 (Estimated)
SponsorCapital Medical University (Other)
ConditionsMechanical Thrombectomy, Stroke, Balloon Guide Catheter
InterventionsBalloon guide catheter, Non-balloon guide catheter (Device)
Datesstart 2018-11-25 (estimated), primary completion 2019-11-25 (estimated), completion 2020-02-28 (estimated), first posted 2018-11-27, last updated 2018-12-04
Locations6 sites in China

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Mechanical Thrombectomy All trials for Stroke All trials of Balloon guide catheter All trials of Non-balloon guide catheter

-Summary

With mechanical thrombectomy now representing standard of care for treatment of acute ischemic stroke secondary to large vessel occlusion, identifying adjunctive techniques that result in improved outcomes for patients with LVO has become an issue of increasing importance. A number of retrospective studies have demonstrated that flow arrest during the clot retrieval process results in less clot fragmentation, lower rates of distal emboli, higher revascularization rates and improved rates of good neurological outcome.

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
Balloon guide catheter groupExperimentalDevice: Balloon guide cathetermechanical thrombectomy with a balloon guide catheter group
Non-balloon guide catheter groupActive comparatorDevice: Non-balloon guide cathetermechanical thrombectomy with a non-balloon guide catheter group
  • Balloon guide catheter (Device): Use a balloon guide catheter in the mechanical thrombectomy
  • Non-balloon guide catheter (Device): Use a non-balloon guide catheter in the mechanical thrombectomy

+Outcome measures

Primary outcomes

  • Distal embolization, [After mechanical thrombectomy, usually within 3 hours]

Secondary outcomes

  • Modified thrombolysis in cerebral infarction 2b/3, [After mechanical thrombectomy, usually within 3 hours]
  • Modified thrombolysis in cerebral infarction [After mechanical thrombectomy, usually within 3 hours]
  • Modified thrombolysis in cerebral infarction 2b/3 after the first pass [After the first pass, , usually within 3 hours]
  • First pass recanalization rate [After the first pass, , usually within 3 hours]
  • Number of passes [After mechanical thrombectomy, usually within 3 hours]
  • Procedure time [From the procedure start to the end, usually within 3 hours]
  • National Institutes of Health Stroke Scale [7 days or discharge]: Scores on the National Institutes of Health Stroke Scale (NIHSS) range from 0 to 42, with higher scores indicating more severe neurologic deficits.
  • Symptomatic intracranial hemorrhage [24 hours]
  • Modified Rankin Scale [90 days]: Scores on the modified Rankin scale of functional disability range from 0 (no symptoms) to 6 (death).
  • Mortality [90 days]

Other outcomes

  • Safety (occurrence of adverse events and serious adverse events) [7 days]

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Age 18 years or older
* A clinical diagnosis of acute stroke, with a deficit on the NIHSS of 2 points or more.
* Intracranial arterial occlusion of the distal intracranial carotid artery or middle (M1/M2) or anterior (A1/A2) cerebral artery, demonstrated with CTA, MRA, or DSA.
* Treatment can be initiated (groin puncture) within 6 hours of symptom onset.
* Planning to mechanical thrombectomy with a stenting retriever.
* Signed informed consent prior to entering study.

Exclusion Criteria:

* Moderate stenosis, severe stenosis, or occlusion of the ipsilateral extracranial carotid artery.
* Previously deployed stents in the ipsilateral carotid artery.
* Dissections of the ipsilateral carotid artery.
* Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR > 3.0.
* Baseline platelet count < 50.000/µL.
* Baseline blood glucose of < 50mg/dL or >400mg/dl.
* Severe, sustained hypertension (SBP > 220 mm Hg or DBP > 110 mm Hg).
* Renal insufficiency with creatinine ≥ 3 mg/dl.
* Patients in sedation and intubated patients could not be included if baseline NIHSS is not obtained by a neurologist or emergency physician prior to sedation or intubation.
* Seizures at stroke onset which would preclude obtaining a baseline NIHSS.
* Unlikely to be available for 90 days follow-up (e.g. no fixed home address, visitor from overseas).
* Subject participating in a study involving an investigational drug or device that would impact this study.

+Locations (6)

FacilityCityCountryStatus
Suzhou Municipal HoapitalSuzhou, AnhuiChinaNot yet recruiting
Xuan Wu Hospital,Capital Medical UniversityBeijing, Beijing MunicipalityChinaRecruiting
Lu He hospital, Capital Medical UniversityBeijing, Beijing MunicipalityChinaRecruiting
Shengli Oilfield Central HospitalDongying, ShandongChinaNot yet recruiting
Nanyang City Center HospitalNanyangChinaRecruiting
The First Affiliated Hospital of Zhengzhou UniversityZhengzhouChinaNot yet recruiting

+Publications

  • Results publication: Ma H, Che R, Zhang Q, Yu W, Wu L, Zhao W, Li M, Wu D, Wu C, Ji X. The optimum anticoagulation time after endovascular thrombectomy for atrial fibrillation-related large vessel occlusion stroke: a real-world study. J Neurol. 2023 Apr;270(4):2084-2095. doi: 10.1007/s00415-022-11515-y. Epub 2023 Jan 3. PMID 36596867

My Notes